NasdaqGM:CRMDPharmaceuticals
CorMedix (CRMD) Is Down 9.4% After Reaffirming 2026 Guidance and Reporting Profit Swing - What's Changed
CorMedix Inc. has reported past fourth-quarter 2025 revenue of US$128.62 million and net income of US$14.02 million, capping a year in which full-year revenue reached US$311.71 million and net income swung to US$163.06 million from a prior loss.
The company’s reiteration of 2026 net revenue guidance of US$300 million to US$320 million, alongside advancing late-stage trials for REZZAYO and other pipeline assets, highlights management’s focus on consolidating recent product gains while...